A Phase 2 study of perifosine in advanced or metastatic breast cancer

[1] Chia SKL(2003)The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort Proc Am Soc Clin Oncol 22 6-168

[2] Speers C(2000)Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer Cancer Treat Rev 26 151-281

[3] Kang A(2001)A systematic overview of chemotherapy effects in breast cancer Acta Oncol 40 253-1161

[4] Stockler M(2006)Addition of drug/s to a chemotherapy regimen for metastatic breast cancer Cochrane Database Syst Rev 3 CD003368-828

[5] Wilcken N(1999)Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer Br J Cancer 79 1158-4159

[6] Ghersi D(2000)Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients Anticancer Drugs 11 825-446

[7] Simes RJ(2001)Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer J Clin Oncol 19 4150-425

[8] Bergh J(1997)D-21266, a new heterocyclic alkylphospholipid with antitumor activity Eur J Cancer 33 442-102

[9] Jonsson PE(1995)Interference of new alkylphospholipid analogues with mitogenic signal transduction Anticancer Drug Des 10 411-2463

[10] Glimelius B(1998)The inhibition of cell signaling pathways by antitumor ether lipids Biochim Biophys Acta 1390 85-173

[1] Chia SKL(2003)The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort Proc Am Soc Clin Oncol 22 6-168

[2] Speers C(2000)Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer Cancer Treat Rev 26 151-281

[3] Kang A(2001)A systematic overview of chemotherapy effects in breast cancer Acta Oncol 40 253-1161

[4] Stockler M(2006)Addition of drug/s to a chemotherapy regimen for metastatic breast cancer Cochrane Database Syst Rev 3 CD003368-828

[5] Wilcken N(1999)Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer Br J Cancer 79 1158-4159

[6] Ghersi D(2000)Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients Anticancer Drugs 11 825-446

[7] Simes RJ(2001)Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer J Clin Oncol 19 4150-425

[8] Bergh J(1997)D-21266, a new heterocyclic alkylphospholipid with antitumor activity Eur J Cancer 33 442-102

[9] Jonsson PE(1995)Interference of new alkylphospholipid analogues with mitogenic signal transduction Anticancer Drug Des 10 411-2463

[10] Glimelius B(1998)The inhibition of cell signaling pathways by antitumor ether lipids Biochim Biophys Acta 1390 85-173